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Effect of Lactobacillus plantarum YIT 0132 on Japanese cedar pollinosis and regulatory T cells in adults
To the editor, Japanese cedar pollinosis (JCPsis) is a major health problem that has increased over recent decades and impairs daily activities. 1 Besides the standard treatments specified in the guidelines, 2 some strains of lactic acid bacteria (LAB), such as Bifidobacterium and Lactobacillus, have been shown to improve pollinosis symptoms. 3, 4 Although LAB are believed to induce regulatory T (Treg) cells, thereby alleviating allergic symptoms, 4 whether LAB augment Treg cell abundance, together with clinical symptoms, remains unclear.
Lactobacillus plantarum YIT 0132 (LP0132), derived from fermented food, induces a high level of IL-10 secretion from murine macrophages. 5 Previously, LP0132-fermented citrus juice, which contained approximately 8.0 × 10 10 heat-killed LP0132 cells/100 mL, showed therapeutic potential to improve JCPsis-associated symptoms. 5 In this trial, we further evaluated the efficacy of this beverage for the treatment of JCPsis, in association with immunological parameters including peripheral Treg cells in the pollen season.
We randomly assigned 100 adults with JCPsis to consume 125 mL of fermented citrus juice containing heat-killed LP0132 (LP0132, n = 50) or unfermented citrus juice (placebo, n = 50) for 8 weeks from mid-February to mid-April 2017, from the beginning to the end of the pollen season ( Figure S1 ). Throughout the trial period, the subjects were asked to avoid taking LAB-containing food and keep daily records of their consumption of beverages, medications, and medical visits, and to perform a weekly self-assessment of JCPsis symptoms based on the Japanese Rhino-conjunctivitis Quality of Life Questionnaire. 2 The primary outcome was total symptom score (TSS) in March (predicted peak season). Peripheral blood samples All subjects completed the trial ( Figure S2 ), and no significant adverse events were reported in either group. The baseline characteristics were comparable, except for the higher symptom medication score (SMS) and medication score (MS) in the LP0132 group (Table   S1 ). Average TSS in March (weeks 3-6) did not differ significantly between both groups; however, the LP0132 group had a significantly F I G U R E 1 Changes in (A) total symptom score (TSS), symptom medication score (SMS), total nasal symptom score (TNSS), and total ocular symptom score (TOSS), and (B) Treg cells in the trial period. Data are expressed as the mean ± SD.
: Figure 1B) . Other immunological parameters did not differ significantly between both groups at each timepoint (Table S2 ). Although MS in the LP0132 group was significantly higher throughout the consumption period, propensity score matching analysis adjusting for MS from weeks 0 to 10 (36 subjects from each group) was consistent with these results ( Figure S3 ).
As a predetermined exploratory analysis, based on the changes in the percentage of Treg cells from enrollment to the consumption period, the subjects in the LP0132 group were divided into increased
Treg and decreased Treg subgroups to compare the symptom scores.
The increased Treg subgroup (n = 17) had a significantly lower TNSS than the decreased Treg subgroup (n = 33) during the consumption period ( Figure 2A ). Propensity score matching analysis adjusting for MS from weeks 0 to 10 (14 subjects from each subgroup) was consistent with these results ( Figure 2B ). In contrast, the same analysis in the placebo group did not show a significant difference between the increased Treg (n = 9) and decreased Treg (n = 41) subgroups.
Despite the negative result for the primary outcome, this is the first clinical trial to demonstrate the ability of LAB to suppress the reduction in Treg cells in the peak pollen season. In a recent trial, LAB increased the percentage of Treg cells from the baseline, but the changes were not significant compared with placebo. 6 Treg cells are reported to be reduced in patients with allergic rhinitis 7
and increased by immunotherapy with a clinical response. 8 The re- in the blood samples were not measured to validate the LP0132 signature, which we will perform in a future study to further elucidate the mechanism underlying the action of LP0132. Propensity score matching to adjust for MS may have missed unrecognized backgrounds, which could lead to the misinterpretation of our results. However, we did not find any factors that were different between the matched groups.
In summary, citrus juice fermented with LP0132 alleviated JCPsis symptoms in the early season and suppressed reduction in circulating Treg cells in the peak season. The increase in Treg abundance from enrollment was associated with milder JCPsis symptoms.
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Additional supporting information may be found online in the Supporting Information section at the end of the article.
Demonstration of human mast cell progenitors in the bone marrow
To the editor Mast cells are tissue-resident cells widely recognized for their role in asthma and allergy. In inflammatory diseases, mast cells accumulate and become activated in particular sites of affected tissues such as, for example in the bronchial smooth muscles of allergic asthmatics. 1 Using in vivo models, we and others have shown that these inflammation-induced mast cells originate from mast cell progenitors (MCp). 2 For decades, human mast cells have been differentiated in vitro from uncommitted progenitor cells isolated from, for example peripheral blood and bone marrow (BM). In the current study, a population of MCp in the BM of healthy adults was identified, which was more frequent, and had lower surface expression of integrin β7 than the recently described MCp population in the blood. 3 Integrin β7 is required for transmigration of mouse MCp into the lung. 4 Thus, we speculate that integrin β7 is upregulated on the human MCp upon release from the BM in preparation for their transmigration from the blood to the peripheral tissues.
Using flow cytometry, BM samples from healthy donors were investigated for the possible presence of a MCp population. In comparison with peripheral blood samples from the same individuals (n = 11), the BM was enriched in lineage (Lin) − (CD4 − CD8 − CD19 − CD14 − ) cells, Lin − CD34 hi cells and Lin − CD34 hi CD117 + cells ( Figure 1A) . A population of Lin − CD34 hi CD117 + FcεRI + cells was found in healthy BM ( Figure 1D ), which was similar but 14-fold more frequent than the known MCp population in peripheral blood ( Figure 1B FcεRI − mast cells have been demonstrated in vitro 5 and shown residing in the alveolar parenchyma in vivo. 6 Regardless, there was no difference in the expression of FcεRI between the BM and blood progenies (39.8% ± 10.2% and 52.7% ± 12.0%, respectively). The BM progeny cells had a similar mast cell-like morphology, determined by May-Grünwald-Giemsa staining ( Figure 1G ), as the blood progeny cells ( Figure 1K ). Further, the progeny cells from both sources expressed various levels of tryptase ( Figure 1H and L) . Altogether, DOI: 10.1111/all.14004
